Antiplatelet therapy is considered essential for secondary prevention of ischemic heart
disease. After percutaneous coronary intervention (PCI), temporary dual antiplatelet therapy …

The ABCD-GENE score was constructed to identify patients with high platelet reactivity
(HPR) after 30 days of clopidogrel treatment. In our study, 1297 eligible patients with acute …

Tailoring antiplatelet therapy based on CYP2C19 pharmacogenetic (PGx) testing can
improve cardiovascular outcomes and potentially reduce healthcare costs in patients on a …

Background CYP2C19 loss-of-function (LOF) alleles reduce the effectiveness of clopidogrel
and are associated with high rates of clinical events in patients undergoing percutaneous …

Objectives To investigate outcomes with selective, clopidogrel-based therapies versus
conventional treatment in patients undergoing percutaneous coronary intervention (PCI) …

目的: 探究冠心病患者服用氯吡格雷后血小板抑制作用达到稳态的时间, 为氯吡格雷药效学研究
提供借鉴. 方法: 入选接受经皮冠状动脉介入治疗且服用氯吡格雷3d 后的冠心病患者 …

Background Clopidogrel is widely used for the secondary prevention of atherothrombotic
events in patients with coronary artery disease (CAD), ischemic stroke, and peripheral …

The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently,
some patients are at increased risk of recurrent ischemic events during treatment. This …

For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary
syndrome (ACS) has been the only class I recommendation on DAPT in American and …

Background: Antiplatelet therapy deescalation has been suggested as an alternative to
standard treatment with potent dual antiplatelet therapy (DAPT) for 1 year in low bleeding …